Panomics

Less than a year after Affymetrix bought eBioscience, the array vendor is finding ways to combine its background in microarray and branched-DNA genotyping and expression with eBio's flow cytometry reagents and multiplex immunoassay portfolios.

This article was originally posted on Feb. 1

Affymetrix this week reported a slight uptick in its second-quarter revenues, which increased 3 percent to $66.4 million from $64.7 million in the year-ago period, beating the average analyst estimate of $65.6 million.